High PD-L1 expression on immune cells along with increased density of tumor-infiltrating lymphocytes predicts a favorable survival outcome for patients with loco-regionally advanced head and neck cancer: early results from a prospective study.
PD-L1 expression
head and neck cancer
immune biomarkers
prognosis
tumor-infiltrating lymphocytes
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2024
2024
Historique:
received:
29
11
2023
accepted:
18
03
2024
medline:
19
4
2024
pubmed:
19
4
2024
entrez:
19
4
2024
Statut:
epublish
Résumé
In the era of personalized medicine and treatment optimization, use of immune biomarkers holds promise for estimating the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) undergoing definitive treatment. To evaluate the prognostic potential of immune biomarkers, we conducted a prospective monocentric cohort study with loco-regionally advanced HNSCC patients indicated for definitive radiotherapy/radiochemotherapy at the Department of Oncology, Ostrava University Hospital, Czech Republic, between June 2020 and August 2023. We focused on the expression of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) relative to overall survival (OS) and specific survival rates. Associations between biomarkers and survival rates were assessed by crude and adjusted hazard ratios (cHR, aHR, respectively) obtained from Cox proportional hazards regression. Among a total of 55 patients within a median follow-up of 19.7 months, there were 21 (38.2%) all-cause deaths and 15 (27.3%) cancer-related deaths. An overall survival (OS) rate of 61.8% and a disease-specific survival (DSS) rate of 72.7% were recorded. A significant association between survival rates and a ≥10% difference in PD-L1 expression on immune versus tumor cells (high PD-L1 The early outcomes of the present study suggest the utility of a strong prognostic factor involving a composite biomarker high PD-L1 The study is registered with Clinicaltrials.gov. - NCT05941676.
Identifiants
pubmed: 38638854
doi: 10.3389/fonc.2024.1346793
pmc: PMC11024328
doi:
Banques de données
ClinicalTrials.gov
['NCT05941676']
Types de publication
Journal Article
Langues
eng
Pagination
1346793Informations de copyright
Copyright © 2024 Blažek, Petráš, Hurník, Matoušek, Knybel, Čermáková, Štembírek, Cvek and Soumarová.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
JAMA Netw Open. 2023 Mar 1;6(3):e236324
pubmed: 37000447
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Pathol Res Pract. 2022 Aug;236:153934
pubmed: 35691098
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Radiat Oncol. 2021 Jun 29;16(1):122
pubmed: 34187494
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668519
Mol Cancer. 2019 Mar 30;18(1):63
pubmed: 30927923
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Biomedicines. 2021 Sep 01;9(9):
pubmed: 34572318
PLoS One. 2017 Jun 12;12(6):e0179536
pubmed: 28604812
Oral Oncol. 2018 Nov;86:81-90
pubmed: 30409325
Cell Prolif. 2019 Mar;52(2):e12537
pubmed: 30443950
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Front Oncol. 2018 Dec 11;8:604
pubmed: 30619746
Cancer Immun. 2008 Dec 04;8:16
pubmed: 19053167
JAMA Otolaryngol Head Neck Surg. 2019 Nov 01;145(11):1012-1019
pubmed: 31486841
Int J Oral Sci. 2021 Aug 2;13(1):24
pubmed: 34341329
PLoS One. 2015 Nov 12;10(11):e0142656
pubmed: 26562534